SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (462)1/1/2004 5:03:37 PM
From: JMarcus  Respond to of 496
 
GLFD is in Ron Garren's model portfolio. In his year-end recap of the stocks in his model portfolio, he had this to say about GLFD:

<<Guilford (GLFD) is a more complicated story with a number of drivers. I think the greatest value still lies in the neuro immunophilin program for Parkinson’s disease. The same drug is also in trials for nerve sparing post-prostatectomy. An aqueous propofol anesthetic in Phase II trials and the recently acquired drug Aggrastat round out their pipeline. The Gliadel wafer is a non-story.>>

Marc



To: Doc Bones who wrote (462)1/1/2004 11:15:53 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 496
 
<<"I'm not 100% objective, but I try to be objective, especially when I'm spending money," he said.>>

What a (cynic) note!

Is he OBJECTIVE (and with restrain) when spending corporate money?


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News